ArticleBiotechnology journal2025
Improvement of the Antimicrobial Peptide Activity by Means of Chitosan-Based Nanoparticles.
Article in Biotechnology journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
This study demonstrated the enhancement of the bioactivity of Cm-p1 and Lip1 antimicrobial peptides (AMPs) against Botrytis cinerea when included within chitosan nanoparticles (CS-NPs). The physicochemical properties of these AMPs and the adequacy of CS-NPs for their encapsulation were predicted by in silico studies. When the antimicrobial activities of the free peptides were analyzed, significant differences were found, but their encapsulation in CS-NPs significantly improved their efficacy in reducing conidia germination and hyphal growth against B. cinerea, resulting in a total inhibition of germination at concentrations greater than 800 µM (Cm-p1) or 6.25 µM (Lip1). Both AMPs were successfully encapsulated into 190-239 nm CS-NPs with encapsulation efficiencies (EE%) greater than 96%, when pH of CS solutions was increased to 4.7, and polydispersity indices below 0.329 by the ionic gelation method. Based on the experimental data obtained, the antimicrobial properties of CS are undoubtedly related to the enhancement of the activity of these AMPs when encapsulated into CS-NPs, although the use of a vector to deliver the AMPs to the cells must be the main cause of this effect. However, further studies are needed to demonstrate the penetration of these peptides through microbial membranes because of their transport within the CS-NPs.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.